Ligand Pharmaceuticals has announced an impressive second quarter for 2026, marked by substantial growth in royalty revenue and pivotal strategic advancements. The company's financial performance reflects a robust 34% increase in total revenue and a 48% rise in adjusted diluted earnings per share. A key highlight was the successful integration of the XOMA Royalty acquisition, a move that significantly diversified Ligand’s asset portfolio and extended the duration of its cash flows. Furthermore, a strategic $700 million convertible note offering bolstered its financial position, providing ample capital for future growth initiatives. This period underscores Ligand's transformation into a more focused, capital-efficient, and royalty-driven enterprise, poised for sustained expansion and innovation in the biopharmaceutical sector.
The second quarter of 2026 was a period of notable financial achievement for Ligand Pharmaceuticals. The company saw its total revenue climb to $63.7 million, a substantial 34% increase from the previous year. This growth was predominantly fueled by a 32% surge in royalty revenue, reaching $48.0 million, attributed to the strong performance of key products such as Filspari, Ohtuvayre, and Zelsuvmi. The adjusted diluted EPS also experienced significant uplift, rising 48% to $2.37, demonstrating the scalability and operational efficiency of Ligand’s business model. Management subsequently updated its 2026 adjusted EPS guidance to $9.00-$9.50, reflecting heightened confidence in its earning potential, while maintaining revenue guidance between $270 million and $310 million.
A cornerstone of Ligand’s strategic expansion during this quarter was the acquisition of XOMA Royalty, finalized shortly after the quarter's end. This monumental transaction, the largest in Ligand’s history, added over 120 commercial, clinical, and preclinical assets to its portfolio. The integration of XOMA is expected to contribute approximately $0.50 per share to adjusted EPS in the latter half of 2026, and an estimated $1.50 per share in 2027, driven by robust growth and extended cash flow duration through 2040. This acquisition not only diversifies Ligand’s risk but also significantly accelerates its growth trajectory, positioning it for higher returns with a broader asset base. The company also anticipates realizing $25 million in annual cost synergies from XOMA, by streamlining operations and eliminating redundant public company infrastructure.
Financially, Ligand fortified its balance sheet with a $700 million 0% coupon convertible note offering. This financing strategically enhanced the company’s capital access, enabling it to pursue attractive investment opportunities more aggressively. With $700 million in deployable capital and projected operating cash flows exceeding $300 million by 2027, Ligand possesses considerable flexibility for future royalty acquisitions. The company also repurchased 228,859 shares for approximately $60 million, reinforcing its commitment to shareholder value. Despite a 17% year-over-year decrease in Kyprolis net sales due to lower volumes, the overall royalty growth from other programs successfully offset this, affirming the resilience of its diversified revenue streams.
Looking ahead, Ligand is entering an unprecedented period of potential clinical and regulatory catalysts. The expanded portfolio now boasts over 70 clinical-stage assets, with up to seven pivotal trial readouts anticipated within the next 18 months across diverse therapeutic areas including rare diseases, oncology, ophthalmology, and autoimmune disorders. Notable programs like Vabysmo, Ojemda, and Filspari are expected to be significant growth drivers. Filspari, having received FDA approval for FSGS, is projected to achieve peak sales exceeding $3 billion. These opportunities, while carrying inherent risks, are managed through Ligand’s highly diversified portfolio, which mitigates dependence on any single product. The company’s strategy of partnering with innovative biotechnology firms allows it to participate in therapeutic advances without assuming the full operational burden of drug development, manufacturing, and commercialization, thereby achieving superior risk-adjusted returns.
The company's strategic evolution since 2022 has transformed it into a more focused and capital-efficient entity, with royalty revenue projected to soar from $73 million in 2022 to an estimated $225 million-$250 million in 2026. This significant growth, combined with disciplined capital deployment and a lean operating model, has dramatically boosted adjusted EPS from $2.44 in 2022 to the updated 2026 guidance range. Ligand’s investment approach prioritizes high-quality royalty opportunities and strategic partnerships, cementing its position as a preferred partner for companies seeking flexible financing solutions. The upcoming Investor Day in December will provide an updated five-year outlook, reflecting the amplified scale, diversification, and growth potential of the business following these recent achievements.
